Hong Kong:
Dr Jeremy Teoh is currently Associate Professor, and the Assistant Dean (External Affairs) of the Faculty of Medicine, The Chinese University of Hong Kong. In 2021, he was awarded the Ten Outstanding Young Persons Award (Hong Kong) and the SIU-Innovators Award. In 2023, he was appointed as an Adjunct Professor at the Medical University of Vienna. In 2024, he was awarded the World Chinese Urological Society Rising Star Award. Jeremy has an immense interest in bladder cancer research. Of note, he conducted a randomised trial comparing between bipolar and monopolar transurethral resection of bladder tumour (TURBT), and showed that bipolar TURBT could achieve a higher detrusor sampling rate than monopolar TURBT. He has also developed a global consensus statement on transurethral en bloc resection of bladder tumour (ERBT).
He also led a multi-centre randomised trial on ERBT, and it was the first multi-centre clinical trial to show that ERBT could reduce the 1-year recurrence rate of non-muscle-invasive bladder cancer (NMIBC) from 38.1% to 28.5%, as compared to TURBT. He is also leading a phase 2 clinical trial investigating the role of modified ERBT for large bladder tumours. Currently, he is heavily involved in the development of urinary biomarkers for bladder cancer, aiming to develop a urine test which can safely avoid the need of cystoscopy in well-selected patients.
Jeremy is also leading a bladder cancer organoid project, aiming to perform drug screening for chemotherapy, targeted treatment and immune-oncology drugs, and finally developing a molecular classification based on treatment response. Jeremy is currently Associate Editor of the European Urology Oncology journal, and a panel member of the European Association Urology (EAU) Guidelines on NMIBC and Upper Tract Urothelial Carcinoma (UTUC).
